INS and type 2 diabetes mellitus: Activation of the GPR44 signaling pathway was assumed to inhibit insulin secretion, but oral administration of a GRP44 inhibitor showed no major impact on insulin secretion in patients with type 2 diabetes [68], albeit demonstrated improvement of islet function under inflammatory and hyperglycemic stress [69].